Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：20

作者：

Takimoto, Takayuki ^{[1
]}

Nakabori, Tasuku ^{[1
]}

Osa, Akio ^{[1
]}

Morita, Satomu ^{[1
]}

Terada, Haruko ^{[1
]}

Oseto, Susumu ^{[1
]}

Iwazawa, Takashi ^{[2
]}

Abe, Kinya ^{[1
]}

机构：

[1] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan

[2] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka 5608565, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 17卷 / 04期

关键词：

Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; beta(2)-Microglobulin; RENAL-FUNCTION; CISPLATIN; CHEMOTHERAPY; PLATINUM; TAXOTERE;

D O I：

10.1007/s10147-011-0304-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

引用

页码：395 / 398

页数：4

共 50 条

[1] Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients
Takayuki Takimoto
Tasuku Nakabori
Akio Osa
Satomu Morita
Haruko Terada
Susumu Oseto
Takashi Iwazawa
Kinya Abe
International Journal of Clinical Oncology, 2012, 17 : 395 - 398
[2] Docetaxel in the treatment of advanced non-small-cell lung cancer
Saloustros, Emmanouel
Georgoulias, Vassilis
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1207 - 1222
[3] Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer
Okamoto H.
Watanabe K.
Segawa Y.
Ichinose Y.
Yokoyama A.
Yoneda S.
Niitani H.
International Journal of Clinical Oncology, 2000, 5 (5) : 316 - 322
[4] Undertreatment of elderly patients with non-small-cell lung cancer
Ng, Raymond
de Boer, Richard
Green, Michael D.
CLINICAL LUNG CANCER, 2005, 7 (03) : 168 - 174
[5] Development of docetaxel in advanced non-small-cell lung cancer
Belani, CP
Eckardt, J
LUNG CANCER, 2004, 46 : S3 - S11
[6] Docetaxel plus cisplatin in non-small-cell lung cancer
Chandra Belani
Sakkaraiappan Ramalingam
Vassilis Georgoulias
George Simon
Drugs & Therapy Perspectives, 2004, 20 (3) : 7 - 9
[7] A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer
Mori, K
Kamiyama, Y
Kondo, T
Kano, Y
Kodama, T
CHEMOTHERAPY, 2005, 51 (2-3) : 120 - 125
[8] Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients
Nagio Takigawa
Yoshihiko Segawa
Daizo Kishino
Keiichi Fujiwara
Yoshiyuki Tokuda
Nobuhiko Seki
Tetsu Shinkai
Yoichi Watanabe
Shunkichi Hiraki
Toshiyuki Kozuki
Kenichi Gemba
Masahiro Tabata
Katsuyuki Kiura
Hiroshi Ueoka
Mitsune Tanimoto
Cancer Chemotherapy and Pharmacology, 2004, 54 : 230 - 236
[9] A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer
Teramoto, Koji
Asada, Yoshikuni
Ozaki, Yoshitomo
Suzumura, Yuji
Nakano, Yasutaka
Sawai, Satoru
Tezuka, Noriaki
Inoue, Shuhei
Fujino, Shozo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 531 - 537
[10] A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer
Koji Teramoto
Yoshikuni Asada
Yoshitomo Ozaki
Yuji Suzumura
Yasutaka Nakano
Satoru Sawai
Noriaki Tezuka
Shuhei Inoue
Shozo Fujino
Cancer Chemotherapy and Pharmacology, 2012, 70 : 531 - 537

← 1 2 3 4 5 →